415 related articles for article (PubMed ID: 33459842)
21. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
[TBL] [Abstract][Full Text] [Related]
22. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy.
Liu Z; Yu Z; Chen D; Verma V; Yuan C; Wang M; Wang F; Fan Q; Wang X; Li Y; Ma Y; Wu M; Yu J
Cancer Commun (Lond); 2022 Oct; 42(10):971-986. PubMed ID: 35962977
[TBL] [Abstract][Full Text] [Related]
23. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
[TBL] [Abstract][Full Text] [Related]
24. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
26. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
[TBL] [Abstract][Full Text] [Related]
27. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
Yu P; Spiotto MT; Lee Y; Schreiber H; Fu YX
J Exp Med; 2003 Apr; 197(8):985-95. PubMed ID: 12695490
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
29. Lymph node targeting strategy using a hydrogel sustained-release system to load effector memory T cells improves the anti-tumor efficacy of anti-PD-1.
Cui H; Zhao YY; Han YH; Lan Z; Zou KL; Cheng GW; Chen H; Zhong PL; Chen Y; Ma LM; Chen TK; Yu GT
Acta Biomater; 2024 May; 180():423-435. PubMed ID: 38641183
[TBL] [Abstract][Full Text] [Related]
30. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8
Sanz-Ortega L; Portilla Y; Pérez-Yagüe S; Barber DF
J Nanobiotechnology; 2019 Aug; 17(1):87. PubMed ID: 31387604
[TBL] [Abstract][Full Text] [Related]
31. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
[TBL] [Abstract][Full Text] [Related]
32. ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes.
Yanguas A; Garasa S; Teijeira Á; Aubá C; Melero I; Rouzaut A
Front Immunol; 2018; 9():2084. PubMed ID: 30258446
[TBL] [Abstract][Full Text] [Related]
33. High Numbers and Densities of PD1
Bronsert P; von Schoenfeld A; Villacorta Hidalgo J; Kraft S; Pfeiffer J; Erbes T; Werner M; Seidl M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32824917
[TBL] [Abstract][Full Text] [Related]
34. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract][Full Text] [Related]
35. Significance of TIM-3 expression by CD4
Shariati S; Ghods A; Zohouri M; Rasolmali R; Talei AR; Mehdipour F; Ghaderi A
Mol Immunol; 2020 Dec; 128():47-54. PubMed ID: 33068833
[TBL] [Abstract][Full Text] [Related]
36. Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens.
Gao J; Yuan X; Yuan J; Li L
Cancer Immunol Immunother; 2021 Nov; 70(11):3291-3302. PubMed ID: 33852044
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
38. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.
Carpenter KJ; Valfort AC; Steinauer N; Chatterjee A; Abuirqeba S; Majidi S; Sengupta M; Di Paolo RJ; Shornick LP; Zhang J; Flaveny CA
Sci Rep; 2019 Dec; 9(1):19530. PubMed ID: 31863071
[TBL] [Abstract][Full Text] [Related]
39. TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.
Hu X; Li G; Li S; Wang Q; Wang Y; Zhang P; Yang T; Yang B; Yu L; Liu Z
Biochem Biophys Res Commun; 2024 Jan; 694():149388. PubMed ID: 38150917
[TBL] [Abstract][Full Text] [Related]
40. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
